HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29
Relay Therapeutics, Inc.
Relay Therapeutics, Inc. RLAY | 0.00 |
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:
RLAY) with a Buy and raises the price target from $28 to $29.
